|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 23-11-10 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 23-07-25 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 2018-08-31 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 2022-12-31 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 2014-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 2014-06-03 |
Eric Cornut
BRD | Director/Board Member | 69 | 2016-08-25 |
Günter von Au
CHM | Chairman | 75 | 2017-09-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| -0.21% | -4.52% | +18.91% | +67.25% | 48.26B | ||
| +0.51% | -5.00% | +38.85% | +117.44% | 40.5B | ||
| +0.72% | -1.01% | -10.20% | +11.66% | 11.85B | ||
| +3.29% | -0.38% | +14.11% | +82.76% | 11.83B | ||
| -1.50% | -0.38% | +24.76% | +138.18% | 9.36B | ||
| -0.86% | -3.20% | +23.76% | +38.38% | 7.5B | ||
| -0.19% | -2.60% | +36.28% | -13.54% | 7.37B | ||
| +0.60% | -1.13% | +19.49% | +208.86% | 7.28B | ||
| -0.32% | -1.85% | -46.31% | +22.01% | 5.19B | ||
| Average | +0.22% | -2.31% | +13.29% | +74.78% | 15.49B | |
| Weighted average by Cap. | +0.22% | -1.85% | +20.86% | +82.04% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















